Identification of TGF-β-activated kinase 1 as a possible novel target for renal cell carcinoma intervention

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Renal cell carcinoma (RCC) is a prevalent malignancy with a poor prognosis.
• TGF-β-activated kinase 1 (TAK1) is implicated in cell survival, apoptosis resistance, and carcinogenesis via nuclear factor-κB (NF-κB) and other pathways.

Purpose of the Study:

• To investigate the role of TAK1 in RCC progression.
• To evaluate TAK1 inhibitors as a potential therapeutic strategy for RCC.

Main Methods:

• Utilized TAK1 inhibitors (LYTAK1, 5Z-7-oxozeanol, NG-25) and shRNA-mediated depletion of TAK1 in RCC cell lines (786-O, A489).
• Assessed NF-κB activation, cell survival, apoptosis, and cytotoxicity.
• Examined TAK1 expression in human RCC tissues.
• Investigated the combined effect of TAK1 inhibition with vinblastine sulfate (VLB).

Main Results:

• TAK1 inhibitors suppressed NF-κB activation and RCC cell survival.
• TAK1 inhibition induced apoptotic cytotoxicity in RCC cells, which was partially reversed by caspase inhibitors.
• Partial TAK1 depletion reduced cell viability and induced apoptosis.
• TAK1 was over-expressed in human RCC tissues, correlating with phosphorylated NF-κB.
• TAK1 inhibition or depletion enhanced VLB efficacy in RCC cells.

Conclusions:

• TAK1 plays a significant role in RCC pathogenesis.
• TAK1 represents a potential therapeutic target for intervention in renal cell carcinoma.
• Combined inhibition of TAK1 with chemotherapy may offer a novel treatment approach for RCC.